This week, team members from the U.S. Army Medical Materiel Development Activity participated with thousands of biotechnology industry professionals from around the world at the Biotechnology Innovation Organization’s annual conference, held June 3-6, 2024, in San Diego.
BIO 2024 is the premier venue for U.S. and international biotechnology industry leaders to learn and share best practices and find ways to integrate and apply developing biotechnologies and research across the industry, including the U.S. Military’s Medical Development Enterprise. Under the banner of the Defense Health Agency, the USAMMDA team is working with representatives from the neighboring Army Medical Development Command and senior command departments to explore future development opportunities.
One of the key functions of USAMMDA is to work with the U.S. Army Medical Research and Development Command’s Medical Technology Transfer Office to formalize relationships with private development organizations and explore future partnership opportunities. Public sector and private industry medical development is a complex, time-consuming and costly endeavor, and coordinating joint efforts in support of the Department of Defense’s development mission is critical to meeting the needs of the U.S. military branch’s medical departments.
BIO 2024 aims to bring together industry and government leaders to generate partnership opportunities and synchronize efforts, providing USAMMDA teams with unparalleled access to biotechnology organizations that help advance the Department of Defense’s development mission, according to Judy Holian, branch chief of USAMMDA’s Research and Technology Applications Office.
“The BIO 2024 convention is a great way for the USAMMDA team to tap into the biotechnology industry and showcase what we do as the Army’s premier medical development activity,” said Holian. “Much of what we do as an organization that supports America’s warfighters is to meet and communicate with industry partners to find innovative solutions that serve the needs of frontline healthcare providers in the Army, Navy, Air Force and Special Forces communities. At BIO 2024, we’ll not only be able to meet with our current biotechnology industry partners, but we’ll also be able to seek out potential future partners who may continue to support Army and DHA biotechnology research, development and sustainment activities.”
USAMMDA currently has more than 20 research and development activities underway across the area of combat casualty care. One of USAMMDA’s key activities is working with Department of Defense stakeholders, the Department of Veterans Affairs and industry partners to find new treatments for military members and veterans suffering from Post-Traumatic Stress Disorder (PTSD). Ongoing research led by USAMMDA’s Warfighter Readiness, Performance and Brain Health Project Management Office aims to investigate pharmacological solutions to the lasting effects of PTSD as well as improve the Department of Defense’s understanding of how to develop optimal treatments for both military members and veterans.
Holian said BIO 2024, which will bring together more than 15,000 industry leaders and biological science professionals, is a key event to identify potential future partners from the pharmaceutical industry to advance the Department of Defense’s PTSD treatment programs.
“Pharmaceutical approaches to PTSD treatment augment standard therapies, and events like BIO 2024 help open a dialogue with experts and industry leaders to broaden the scope of our efforts to provide better solutions for military healthcare providers and those with PTSD,” she said.
“Some of USAMMDA’s niche efforts are not as widely known as our efforts directly supporting Joint Military Medical Command and frontline healthcare providers across the military, but they are just as vitally important to develop and sustain,” she added. “Participating in events like BIO 2024 deepens our understanding of the current state and direction of the biotech industry and how we can best align our research and development efforts to build solutions that meet the needs of the U.S. Military and neighboring federal agencies like the VA.”
USAMMDA, a division of USAMRDC based at Fort Detrick, Maryland, is comprised of four project management offices. Working with DoD, non-DoD agencies, and government stakeholders, team members in each PMO develop and deliver life-saving and life-supporting devices, treatments, medicines, vaccines, and medical support equipment for the military joint force.
To learn more about USAMMDA and how to partner with the U.S. Army Medical Development Enterprise, visit https://usammda.health.mil/
Photographed on: June 6, 2024 Posted on: June 6, 2024 16:50 Story ID: 473241 Location: San Diego, California, USA Web Views: 82 Downloads: 0 Public Domain
This work, the USAMMDA team will join global biotech industry leaders at the annual conference in San Diego. The author is TT Parish, who has been identified by DVIDS and must comply with the restrictions set forth at https://www.dvidshub.net/about/copyright.
